Favorable mutations include PML::RARA and RUNX1::RUNX1T1, while adverse mutations involve TP53, FLT3, and KMT2A rearrangements. The use of cytogenetics, FISH, and NGS panels aids in classification ...

Alternative treatments with fewer long-term side effects are urgently needed. We concluded from our study that Runx1t1 is essential for MYCN-driven tumorigenesis. This is a major finding that opens up ...

By blocking the gene, known as RUNX1T1, researchers found they could stop the development of tumours in mice bred to develop neuroblastoma. Professor Murray Norris, who led the research published ...

random forest, decision tree, logistic regression, naive Bayes) and recursive feature elimination-cross validation was used to prediction impairment biomarkers. We found that identified biomarkers ...

Researchers have developed a new form of gene therapy that can stop cell division in fusion-driven cancer. A new study presents a promising treatment method for so-called fusion-driven cancers ...

Concomitant SM-AHN was diagnosed in 17.4% of patients with acute myeloid leukemia with RUNX1::RUNX1T1 via CD117 and CD25 immunohistochemistry staining in postinduction bone marrow sections. The ...

Spleen weights of RUNX1‐RUNX1T1 or I1DN tumor‐bearing mice treated with AG636 or vehicle for 4 days. B, C. Absolute number of leukemic cells in the bone marrow (B) and spleens (C) of RUNX1‐RUNX1T1 or ...